remsima 120 mg/1 ml rastvor za injekciju
oktal pharma d.o.o. sarajevo - infliksimab - rastvor za injekciju - 120 mg/1 ml - 1 ml rastvora za injekciju sadrži: 120 mg infliksimaba
remsima 120 mg/1 ml rastvor za injekciju
oktal pharma d.o.o. sarajevo - infliksimab - rastvor za injekciju - 120 mg/1 ml - 1 ml rastvora za injekciju sadrži: 120 mg infliksimaba
remsima 120 mg/1 ml rastvor za injekciju
oktal pharma d.o.o. sarajevo - infliksimab - rastvor za injekciju - 120 mg/1 ml - 1 ml rastvora za injekciju sadrži: 120 mg infliksimaba
remsima 120 mg/1 ml rastvor za injekciju
oktal pharma d.o.o. sarajevo - infliksimab - rastvor za injekciju - 120 mg/1 ml - 1 ml rastvora za injekciju sadrži: 120 mg infliksimaba
jayempi
nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
idacio 40 mg/0.8 ml otopina za injekciju
pontus pharma d.o.o.sarajevo - adalimumab - otopina za injekciju - 40 mg/0.8 ml - 1 bočica s jednokratnom dozom od 0,8 ml sadrži 40 mg adalimumaba.
imuran 50 mg/1 tableta film tableta
clinres farmacija d.o.o. - azatioprin - film tableta - 50 mg/1 tableta - 1 film tableta sadrži: 50 mg azatioprina
eritromicin farmavita 250 mg/1 kapsula kapsula, tvrda
farmavita d.o.o. sarajevo - eritromicin - kapsula, tvrda - 250 mg/1 kapsula - 1 kapsula, tvrda sadrži: 250 mg eritromicina (u obliku eritromicinestolata)